Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Cerity Partners LLC

Cerity Partners LLC lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 18.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,548 shares of the biopharmaceutical company's stock after purchasing an additional 2,423 shares during the period. Cerity Partners LLC's holdings in Regeneron Pharmaceuticals were worth $16,344,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of REGN. Great Valley Advisor Group Inc. boosted its position in shares of Regeneron Pharmaceuticals by 5.0% in the third quarter. Great Valley Advisor Group Inc. now owns 442 shares of the biopharmaceutical company's stock worth $465,000 after purchasing an additional 21 shares during the period. Meridian Wealth Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 5.7% during the 3rd quarter. Meridian Wealth Management LLC now owns 1,019 shares of the biopharmaceutical company's stock valued at $1,071,000 after buying an additional 55 shares in the last quarter. Icon Wealth Advisors LLC boosted its holdings in Regeneron Pharmaceuticals by 18,342.0% in the 3rd quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company's stock worth $79,874,000 after buying an additional 75,569 shares during the period. Raymond James Trust N.A. increased its stake in Regeneron Pharmaceuticals by 2.9% in the 3rd quarter. Raymond James Trust N.A. now owns 1,064 shares of the biopharmaceutical company's stock worth $1,119,000 after buying an additional 30 shares in the last quarter. Finally, HealthInvest Partners AB raised its holdings in Regeneron Pharmaceuticals by 2.0% during the third quarter. HealthInvest Partners AB now owns 7,028 shares of the biopharmaceutical company's stock valued at $7,388,000 after acquiring an additional 135 shares during the period. 83.31% of the stock is owned by institutional investors.

Insider Activity

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the company's stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares of the company's stock, valued at $18,447,575.65. This represents a 27.07 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Company insiders own 7.48% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. Leerink Partnrs downgraded Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 24th. StockNews.com cut shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Monday, November 4th. JPMorgan Chase & Co. dropped their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an "overweight" rating for the company in a research report on Thursday, October 24th. Finally, Barclays cut their target price on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an "overweight" rating for the company in a research note on Friday, November 1st. One research analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $1,099.55.

Regeneron Pharmaceuticals Stock Down 0.1 %

REGN traded down $0.82 on Tuesday, hitting $748.69. The company had a trading volume of 416,066 shares, compared to its average volume of 541,591. The stock has a market capitalization of $82.27 billion, a price-to-earnings ratio of 18.55, a P/E/G ratio of 2.84 and a beta of 0.15. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The stock has a fifty day moving average price of $937.00 and a 200-day moving average price of $1,025.99. Regeneron Pharmaceuticals, Inc. has a 12-month low of $735.95 and a 12-month high of $1,211.20.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.